Reviewing West Pharmaceutical Services (NYSE:WST) & Remedent (OTCMKTS:REMI)

Remedent (OTCMKTS:REMI) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Profitability

This table compares Remedent and West Pharmaceutical Services’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Remedent	N/A	N/A	N/A
West Pharmaceutical Services	16.29%	18.16%	13.45%

Insider and Institutional Ownership

93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.5% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Remedent has a beta of -0.51, indicating that its share price is 151% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Earnings & Valuation

This table compares Remedent and West Pharmaceutical Services”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Remedent	$990,000.00	N/A	-$270,000.00	($0.01)	-0.06
West Pharmaceutical Services	$2.89 billion	6.83	$492.70 million	$6.75	40.69

West Pharmaceutical Services has higher revenue and earnings than Remedent. Remedent is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Remedent and West Pharmaceutical Services, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Remedent	0	0	0	0	0.00
West Pharmaceutical Services	0	4	8	2	2.86

West Pharmaceutical Services has a consensus price target of $335.78, indicating a potential upside of 22.24%. Given West Pharmaceutical Services’ stronger consensus rating and higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Remedent.

Summary

West Pharmaceutical Services beats Remedent on 14 of the 14 factors compared between the two stocks.

About Remedent

Remedent, Inc. researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products in the United States and internationally. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company also offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. In addition, it provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient’s teeth. Further, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice that enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner. Additionally, it provides dental implant solutions and treatment concepts. The company sells its products through internal sales force and third party distributors. Remedent, Inc. was incorporated in 1986 and is headquartered in Ghent, Belgium.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.